Health Haven
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Hormone Replacement Therapy (HRT)
West Palm Beach, FL
Ketamine Therapy clinics in West Palm Beach
West Palm Beach has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Florida has a dense concentration of ketamine clinics and active FDOH enforcement against non compliant telehealth prescribing of controlled substances. Most West Palm Beach clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in West Palm Beach only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in West Palm Beach, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in West Palm Beach sits in the standard range: single IV infusions run 500 to 900 dollars, a full 6 session protocol lands at 3,000 to 5,400, and Spravato copays depend on insurance coverage. A reputable West Palm Beach ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Doctor Tendler
- Transcranial Magnetic Stimulation (TMS)
- Neurofeedback Therapy
- Ketamine Therapy
Ambrosia Behavioral Health
- Transcranial Magnetic Stimulation (TMS)
- Neurofeedback Therapy
- Ketamine Therapy
- Psychedelic Therapy
Regulatory context
A note on Florida's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Florida Comprehensive Drug Abuse Prevention and Control Act
Mirrors federal scheduling; psilocybin, MDMA, and ibogaine remain Schedule I. -
Florida Office-Based Anesthesia Rule (64B8-9.009)
Applies to office-based procedures including ketamine infusions above moderate sedation thresholds, requiring specific registration and protocols.
Florida enforces federal scheduling. The Florida Board of Medicine and Board of Osteopathic Medicine oversee prescriber conduct, with heightened scrutiny on office-based anesthesia and controlled substance prescribing since the state's pain clinic crackdowns. DEA enforcement targets ketamine diversion and compounding. Florida's E-FORCSE PDMP requires controlled substance reporting. Ryan Haight Act applies to telehealth ketamine prescriptions.